Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Earnings

Medicure Reports Financial Results for Quarter Ended June 30, 2025

By The Northwire Desk — AI Analysis Aug 20, 2025 · 17:30 MPH · 1.05 Medicure Inc.
MPH · Price

Executive Summary

  • Medicure Inc. reported its financial results for the quarter ended June 30, 2025, showing a reduction in net loss compared to the same period in the prior year.
  • Total net revenue increased to $6.7 million from $5.2 million in Q2 2024, driven primarily by growth in the Marley Drug business and pharmacy acquisitions.
  • The company reported an adjusted EBITDA loss of $28,000, an improvement from the $514,000 loss in Q2 2024, while continuing to invest $741,000 in R&D for its investigational product MC-1.

Key Details

  • Total Net Revenue: $6.7 million for Q2 2025, compared to $5.2 million for Q2 2024.
  • AGGRASTAT® Revenue: $1.7 million in Q2 2025, compared to $1.8 million in Q2 2024.
  • Marley Drug Business Revenue: $3.1 million in Q2 2025, compared to $2.7 million in Q2 2024.
    • ZYPITAMAG® sales via Marley Drug: $908,000 (up from $790,000).
    • Other pharmacy revenue: $2.2 million (up from $1.9 million).
  • ZYPITAMAG® Total Revenue: $1.7 million in Q2 2025, compared to $1.4 million in Q2 2024.
    • Insured business channel: $751,000 (up from $654,000).
    • Marley Drug channel: $908,000 (up from $790,000).
  • Gateway Pharmacy Revenue: $764,000 (new acquisition, no prior year comparison).
  • West Olympia Pharmacy Revenue: $328,000 (new acquisition, no prior year comparison).
  • R&D Expenses: $741,000 invested in Q2 2025, supporting the Phase 3 trial of MC-1 for PNPO deficiency.
  • Adjusted EBITDA: Negative $28,000 in Q2 2025, compared to negative $514,000 in Q2 2024.
  • Net Loss: $786,000 ($0.08 per share) in Q2 2025, compared to $1.2 million ($0.12 per share) in Q2 2024.
  • Cash Position: Unrestricted cash totaled $4.7 million at June 30, 2025, down from $7.2 million at December 31, 2024.
  • Cash Flow (Six Months Ended June 30, 2025):
    • Cash used in operating activities: $73,000.
    • Cash used in investing activities: $2.2 million (primarily acquisitions of Gateway and West Olympia Pharmacies).
  • Balance Sheet Highlights (June 30, 2025):
    • Total Assets: $28.4 million.
    • Total Liabilities: $10.1 million.
    • Total Equity: $18.3 million.
    • Goodwill: $4.3 million.
    • Intangible Assets: $8.7 million.

Notable Quotes

  • No direct quotes from the CEO/President were included in the provided text.
Read the original news release →

More from Medicure Inc.

May 21, 2026 · 17:00

Medicure Inc.

Earnings Apr 23, 2026 · 18:15

Cash Burn Accelerates as Medicure Reports 7x Loss Widening Amid Pharmacy Expansion

Earnings Nov 19, 2025 · 17:11

SEDAR Interim Financial Statements

None Nov 19, 2025 · 17:00

Medicure Reports Financial Results for Quarter Ended September 30, 2025

Earnings Nov 13, 2025 · 17:30

Medicure To Present Financial Results on November 20, 2025 Call at 8:30 AM ET for Quarter Ended September 30, 2025

Earnings